X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DISHMAN PHARMA ALEMBIC PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 27.3 25.1 108.9% View Chart
P/BV x 5.5 3.3 164.6% View Chart
Dividend Yield % 0.6 0.7 92.8%  

Financials

 ALEMBIC PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs645374 172.3%   
Low Rs470129 364.5%   
Sales per share (Unadj.) Rs166.1197.8 84.0%  
Earnings per share (Unadj.) Rs21.921.2 103.3%  
Cash flow per share (Unadj.) Rs27.534.7 79.2%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.70.8 90.3%  
Book value per share (Unadj.) Rs117.8179.9 65.5%  
Shares outstanding (eoy) m188.5280.69 233.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 263.8%   
Avg P/E ratio x25.511.9 214.5%  
P/CF ratio (eoy) x20.37.2 279.8%  
Price / Book Value ratio x4.71.4 338.4%  
Dividend payout %18.39.4 193.7%   
Avg Mkt Cap Rs m105,09020,306 517.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m6,2285,355 116.3%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m31,30815,961 196.2%  
Other income Rs m70265 26.5%   
Total revenues Rs m31,37816,226 193.4%   
Gross profit Rs m6,4314,103 156.7%  
Depreciation Rs m1,0551,091 96.7%   
Interest Rs m34944 3.6%   
Profit before tax Rs m5,4132,334 231.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-811 -7,354.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,204624 193.0%   
Profit after tax Rs m4,1281,711 241.3%  
Gross profit margin %20.525.7 79.9%  
Effective tax rate %22.226.7 83.2%   
Net profit margin %13.210.7 123.0%  
BALANCE SHEET DATA
Current assets Rs m18,24711,018 165.6%   
Current liabilities Rs m11,2359,517 118.1%   
Net working cap to sales %22.49.4 238.2%  
Current ratio x1.61.2 140.3%  
Inventory Days Days86110 77.4%  
Debtors Days Days6135 176.1%  
Net fixed assets Rs m20,03516,304 122.9%   
Share capital Rs m377161 233.6%   
"Free" reserves Rs m21,82412,907 169.1%   
Net worth Rs m22,20114,516 152.9%   
Long term debt Rs m5,0004,189 119.3%   
Total assets Rs m39,41129,805 132.2%  
Interest coverage x160.23.5 4,615.2%   
Debt to equity ratio x0.20.3 78.0%  
Sales to assets ratio x0.80.5 148.3%   
Return on assets %10.68.9 118.5%  
Return on equity %18.611.8 157.7%  
Return on capital %19.717.5 112.5%  
Exports to sales %46.424.8 187.3%   
Imports to sales %10.53.7 281.1%   
Exports (fob) Rs m14,5353,956 367.4%   
Imports (cif) Rs m3,288596 551.5%   
Fx inflow Rs m14,7224,952 297.3%   
Fx outflow Rs m7,026697 1,008.3%   
Net fx Rs m7,6964,255 180.9%   
CASH FLOW
From Operations Rs m3,1242,786 112.1%  
From Investments Rs m-8,844-1,529 578.4%  
From Financial Activity Rs m5,026-941 -534.1%  
Net Cashflow Rs m-693316 -219.1%  

Share Holding

Indian Promoters % 74.1 61.4 120.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 3.7 78.4%  
FIIs % 9.1 12.7 71.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 22.1 62.9%  
Shareholders   49,328 46,261 106.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS